Back to investors
CALIGAN PARTNERS LP
CALIGAN PARTNERS LP
Latest filing: 2026-06-30
CALIGAN PARTNERS LP runs CALIGAN PARTNERS LP and currently holds 28 stock positions, which is fewer than the average of 230 among the investors we track. The portfolio is valued at approximately $2.13B. Their top holdings are LQDA, RVMD, ABVX, PCVX, EXEL. The top five represent 67.5% of reported portfolio weight. CALIGAN PARTNERS LP ranks #7 out of 1000 investors tracked by Alpha Score. In the most recent quarter, CALIGAN PARTNERS LP initiated 2 new positions. They added to 6 existing positions. They trimmed 2 positions. Their current best-performing preview position is LQDA with returns of +111.26%.
Sign in to enable email alerts for this investor.
Showper page
28 stock holdings
| Holding | Weight | Avg Buy | Current | Return | Quarter Change |
|---|---|---|---|---|---|
 LQDA LIQUIDIA CORPORATION | 30.45% | $6.98 | $68.62 | +883.09% | Held |
 RVMD REVOLUTION MEDICINES INC | 17.28% | $78.48 | $209.46 | +166.90% | Added +18.69% |
 ABVX ABIVAX SA | 9.77% | $15.51 | $114.95 | +641.13% | Added +6.57% |
 PCVX VAXCYTE INC | 5.99% | $48.79 | $62.62 | +28.35% | Added +6.21% |
 EXEL EXELIXIS INC | 3.98% | $21.13 | $54.08 | +155.94% | Held |
 TNGX TANGO THERAPEUTICS INC | 3.68% | $9.68 | $23.88 | +146.69% | Added +3.79% |
 XENE XENON PHARMACEUTICALS INC | 2.53% | $51.40 | $60.77 | +18.23% | Trimmed -36.11% |
 ADMA ADMA BIOLOGICS INC | 2.25% | $12.11 | $9.84 | -18.74% | Added +20.36% |
 LBRX LB PHARMACEUTICALS INC | 2.20% | $24.66 | $47.62 | +93.11% | Held |
 IMCR IMMUNOCORE HLDGS PLC | 2.06% | $31.75 | $36.88 | +16.16% | New Buy |
Showing 1-10 of 28